共 245 条
- [1] Weber EW(2020)The emerging landscape of immune cell therapies Cell 181 46-62
- [2] Maus MV(2015)Short view of leukemia diagnosis and treatment in Iran Int J Hematol-Oncol Stem Cell Res 9 88-1197
- [3] Mackall CL(2017)Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts EMBO Mol Med 9 1183-594
- [4] Azad M(2019)Limitations in the design of chimeric antigen receptors for cancer therapy Cells 8 472-527
- [5] Hartmann J(2019)CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy Front Immunol 10 2683-12
- [6] Stoiber S(2021)Chimeric antigen receptor-T cells: a pharmaceutical scope Front Pharmacol 12 720692-1471
- [7] Burger MC(2022)FDA approval summary: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma Oncologist 27 587-144
- [8] Hernández-López A(2021)Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Gene Ther 28 513-664
- [9] Bouchkouj N(2021)US Food and Drug Administration approves Bristol Myers Squibb's and Bluebird Bio's Abecma (idecabtagene vicleucel), the first anti-Bcma car T cell therapy for relapsed or refractory multiple myeloma Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple survival 5 11-114
- [10] Albinger N(2022)sBCMA plasma level dynamics and anti-BCMA CAR-T-Cell treatment in relapsed multiple myeloma Curr Issues Mol Biol 44 1463-579